Plasma Fractionation Market to Reach USD 72.86 Billion by 2034, Growing from USD 35.22 Billion in 2024 at a 7.54% CAGR

The global plasma fractionation market size is calculated at USD 37.87 billion in 2025 and is expected to reach around USD 72.86 billion by 2034, growing at a CAGR of 7.54% for the forecasted period.

Ottawa, Oct. 30, 2025 (GLOBE NEWSWIRE) -- The global plasma fractionation market size was valued at USD 35.22 billion in 2024 and is predicted to hit around USD 72.86 billion by 2034, rising at a 7.54% CAGR, a study published by Towards Healthcare a sister firm of Precedence Research.

The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.towardshealthcare.com/download-sample/5320

Key Takeaways

North America held a major share of the market in 2024.
Europe is expected to grow at the fastest CAGR in the studied years.
By type, the immune globulin segment led the plasma fractionation market in 2024.
By type, the coagulation factor segment is expected to grow notably during 2025-2034.
By application type, the hospital segment registered dominance in the market in 2024.
By application type, the retail pharmacy segment is expected to witness rapid expansion in the coming years.

What is Plasma Fractionation?

The global plasma fractionation market mainly refers to the involvement of the process of separation of blood plasma into its individual protein components, especially albumin, immunoglobulins, and clotting factors, for therapeutic use. The growing geriatric population, escalating use of immunoglobulins and coagulation factors, and breakthroughs in fractionation technology are supporting the global market progression. The leading companies are emphasising improvements in safety and purity through sophisticated techniques, including chromatography and viral filtration.

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

What are the Key Drivers in the Plasma Fractionation Market?

A prominent driver is the increasing number of primary immunodeficiency, autoimmune diseases, and haemophilia, which are fueling demand for plasma-derived therapies. Alongside, the involvement of many key players in their expansion of plasma collection centers and inventories, which fulfil the rising demand for plasma. Continuous developments in higher-concentration immunoglobulins and new hyperimmune globulins that target developing infectious diseases are also impacting the overall market growth.

What are the Major Trends in the Plasma Fractionation Market?

In October 2025, Biolab Holdings, Inc., a Phoenix-based medical manufacturer specialising in wound care products, entered into its strategic investment and commercialization partnership with Terraplasma Medical GmbH, a German company innovating the development of plasmapax, a portable cold atmospheric plasma (CAP) device.
In August 2025, GC Biopharma, a South Korean biopharmaceutical company, signed a Memorandum of Understanding (MoU) with the Thai Red Cross Society (TRCS) to cooperate on workforce training for the manufacturing of plasma-derived medicinal products.
In March 2025, Kenox Pharmaceuticals and Lactiga US partnered to boost the progression of new mucosal-targeted secretory IgA (sIgA) therapies, aiming to escalate immunity for immunodeficient individuals.

What is the Emerging Challenge in the Plasma Fractionation Market?

The market is mainly facing a hurdle is a limited and often unstable supply of plasma. In some cases, the market faces the generation of blood wastage, regulatory obstacles to new market entrants, and the restricted availability of some required plasma products, especially in regions like India.

Become a valued research partner with us - https://www.towardshealthcare.com/schedule-meeting

Regional Analysis

How did North America Dominate the Market in 2024?

In 2024, North America captured the biggest revenue share of the market. The possession of robust plasma collection infrastructure, raised demand for therapies to treat chronic diseases, neurological disorders (like stroke), and rare diseases, and ongoing research activities are propelling the plasma fractionation market progression. Besides this, diverse companies are fostering the implementation of AI algorithms to optimise donor management, from recruitment and scheduling to predicting demand.

For instance,

In April 2025, Drummond Scientific Company secured an exclusive license to advance centrifuge-free liquid plasma separation and collection technology from Tufts University.

Why did Europe Grow Notably in the Market in 2024?

Europe is anticipated to expand at a rapid CAGR during 2025-2034 in the plasma fractionation market. Europe is exploring wider innovations in fractionation processes, particularly advanced chromatography techniques and pathogen reduction technologies, as well as favourable government regulations, accelerated healthcare funding, and strategic initiatives. This further promotes domestic plasma collection and production. Moreover, the region is escalating significant investment in new facilities and planned acquisitions to foster plasma collection networks.

For instance,

In July 2025, Grifols, one of the world’s major producers of plasma-derived medicines, invested EUR 160 million in a new facility in Lliçà de Vall (Barcelona), to promote its industrial footprint in Spain and double its plasma fractionation capacity in Europe.

Download the single region market report @ https://www.towardshealthcare.com/checkout/5320

US FDA and EMA: Approved Plasma-Derived Therapies in 2024-2025

US FDA
Alyglo	For treating primary humoral immunodeficiency,
Concizumab	For haemophilia A or B
Fitusiran	For the prevention or reduction of the frequency of bleeding episodes in patients with haemophilia A or B
EMA
Hyqvia	For patients of all ages with chronic inflammatory demyelinating polyneuropathy (CIDP)
Adzynma	For congenital thrombotic thrombocytopenic purpura (cTTP)
Deqsiga	For diverse immunodeficiency and autoimmune diseases.

Segmental Insights

By type analysis

Which Type Led the Plasma Fractionation Market in 2024?

The immune globulin segment accounted for a dominant share of the market in 2024. This type usually possesses a wider range of applications in chronic inflammatory conditions and blood disorders, which boosts demand. Whereas, various pharmaceutical companies are increasingly investing in and emerging novel intravenous (IVIg) and subcutaneous (SCIG) immunoglobulin formulations.

However, the coagulation factor segment is predicted to expand at a lucrative CAGR. Nowadays, researchers are emphasising the elimination of prions, improving FVIII and IX purity, expanding prothrombin complex products, and demonstrating the roles of factors like FXII in coagulation. The latest chromatography is supporting the purification of fibrinogen, and fibrin sealants are now developed by integrating purified fibrinogen and thrombin concentrates.

By application type analysis

What Made the Hospital Segment Dominant in the Market in 2024?

The hospital segment held a major revenue share of the plasma fractionation market in 2024. The globe is facing a major rise in chronic diseases, surgical procedures, and the rising demand for plasma-derived therapies. Additionally, hospitals provide vital treatments, such as IVIg and albumin, for immune deficiencies, liver diseases, and trauma cases. As well as continuous optimisations in plasma collection, storage, and fractionation technologies are impacting the accessibility and availability of plasma treatments in hospitals.

On the other hand, the retail pharmacy segment is estimated to expand rapidly in the predicted timeframe. Ongoing greater government investments in healthcare infrastructures, the accelerating use of plasma-derived therapies, which are easily available in these pharmacies, are boosting the ultimate expansion. A pharmacist of these pharmacies possesses the knowledge regarding the proper storage and handling of these fragile products, some of which are packaged as pre-filled syringes or ready-to-use vials.

Get the latest insights on life science industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership

What are the Revolutionary Developments in the Plasma Fractionation Market?

In August 2025, Kedrion received the grant from the US Food and Drug Administration (FDA) Orphan Drug Designation for an investigational plasma-derived treatment for Congenital Aceruloplasminemia.
In August 2025, Kamada Ltd., a global biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved the supplement to its existing Biologics License Application (BLA) for Kamada Plasma’s collection center in Houston, TX.
In June 2025, Takeda received the U.S. Food and Drug Administration (FDA) approval for GAMMAGARD LIQUID ERC [immune globulin infusion (human)] as replacement therapy for people two years of age and older with primary immunodeficiency (PI).

Browse More Insights of Towards Healthcare:

The global cold plasma market reached a valuation of US$ 2.92 billion in 2024, is projected to rise to US$ 3.34 billion in 2025, and is expected to achieve US$ 11.14 billion by 2034, expanding at a CAGR of 14.35% during the forecast period.

The specialty control plasma market was valued at US$ 10.42 billion in 2024, increased to US$ 11.09 billion in 2025, and is anticipated to reach approximately US$ 19.42 billion by 2034, growing at a CAGR of 6.44% between 2025 and 2034.

The blood bank and plasma freezer market was valued at US$ 95 million in 2023 and is predicted to grow to US$ 168.36 million by 2034, recording a CAGR of 5.34% from 2024 to 2034.

The plasma protein products market was worth US$ 32.8 billion in 2023 and is forecasted to reach US$ 72.9 billion by 2034, advancing at a CAGR of 7.53% over the assessment period.

The plasma-derived medicine market stood at US$ 15.96 billion in 2023 and is projected to expand to US$ 37.4 billion by 2034, with a steady CAGR of 8.05% from 2024 to 2034.

The blood plasma freezer market accounted for US$ 542 million in 2023 and is expected to rise to US$ 903.01 million by 2034, progressing at a CAGR of 4.75% between 2024 and 2034.

The blood plasma fractionation market was valued at US$ 30.93 billion in 2023 and is projected to grow significantly to US$ 74.74 billion by 2034, expanding at a CAGR of 8.35% throughout the forecast period.

Plasma Fractionation Market Key Players List

Syntegon
CSL Behring
Grifols Therapeutics
Mitsubishi Tanabe
Octapharma AG
Hualan Bio
Kedrion S.p.A
Takeda Pharmaceutical Company Ltd.
LFB Group
Intas Pharmaceuticals Ltd.
Biotest AG
Bio Product Laboratory Ltd.

Download the Competitive Landscape market report @ https://www.towardshealthcare.com/checkout/5320

Segments Covered in this Report

By Type

Albumin
Immune Globulin
Coagulation Factor
Others

By Application

Hospital
Retail Pharmacy
Other

By Region

North America
- U.S.
- Canada
Asia Pacific
- China
- Japan
- India
- South Korea
- Thailand
Europe
- Germany
- UK
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
Latin America
- Brazil
- Mexico
- Argentina
Middle East and Africa (MEA)
- South Africa
- UAE
- Saudi Arabia
- Kuwait

Immediate Delivery Available | Buy This Premium Research @ https://www.towardshealthcare.com/checkout/5320

Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.

Access the Dashboard: https://www.towardshealthcare.com/access-dashboard

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

Europe Region: +44 778 256 0738

North America Region: +1 8044 4193 44

APAC Region: +91 9356 9282 04

Web: https://www.towardshealthcare.com

Our Trusted Data Partners

Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.